indium In 111 FPI-2071

A radioimmunoconjugate composed of FPI-2053, a humanized bispecific antibody targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), conjugated to the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and radiolabeled with the radioisotope indium In 111, with potential radioimaging activity. Upon administration of indium In 111 FPI-2071, the FPI-2053 moiety targets and binds to the extracellular domains of both EGFR and c-Met expressed on certain cancer cells, followed by internalization and retention of the radioisotope. This allows for imaging of EGFR- and c-Met-expressing tumor cells using gamma scintigraphy. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. EGFR and c-Met are co-expressed on the surface of various cancer cell types while co-expression on normal, healthy cells is minimal.